AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Revolution Medicines Inc. (RVMD)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

41.45

0.78 (1.92%)

At close: Feb 18, 2025, 3:59 PM

41.27

-0.43%

After-hours: Feb 18, 2025, 04:02 PM EST

undefined% (undefined)

Bid	39.5
Market Cap	7.56B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.66
PE Ratio (ttm)	-11.33
Forward PE	n/a
Analyst	Buy

Ask	46.77
Volume	641,459
Avg. Volume (20D)	1,544,915
Open	40.73
Previous Close	40.67
Day's Range	40.71 - 41.74
52-Week Range	28.43 - 62.40
Beta	undefined

About RVMD

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 13, 2020

Employees 490

Stock Exchange NASDAQ

Ticker Symbol RVMD

Website https://www.revmed.com

Full Company Profile

Analyst Forecast

According to 11 analyst ratings, the average rating for RVMD stock is "Buy." The 12-month stock price forecast is $67, which is an increase of 61.64% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Revolution Medicines Inc. is scheduled to release its earnings on Mar 4, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

-10.46%

Revolution Medicines shares are trading lower. The... Unlock content with Pro Subscription

7 months ago

+10.97%

Revolution shares are trading higher after the company announced that it will host an investor webcast to provide an update on its RMC-6236 pancreatic ductal adenocarcinoma clinical development program.

News

1 week ago · zacks.com

Does Revolution Medicines (RVMD) Have the Potential to Rally 74.05% as Wall Street Analysts Expect?

The mean of analysts' price targets for Revolution Medicines (RVMD) points to a 74.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement a...

1 month ago · zacks.com

Revolution Medicines (RVMD) Loses -7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Revolution Medicines (RVMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earning...

2 months ago · 247wallst.com

Insiders Are Loving These 6 Stocks Right Now

The year is winding down, and the stock markets are near all-time highs. Opinions on what the new year will bring vary wildly.

2 months ago · seekingalpha.com

Revolution Medicines: Risky Buy On Recent Share Price Dip

Revolution Medicines' stock has surged over 30% since April, driven by promising clinical data for its lead asset, RMC-6236, targeting RAS-mutated cancers. RMC-6236 shows best-in-class efficacy in PDA...